US Stock Market Movement: Eli Lilly Surges on October 7th as Target Price is Raised and Weight Loss Drug Announced

Eli Lilly's Surge on October 7: Analysis

Keywords: Price target raise, weight loss drug

1. On October 7, Morgan Stanley analysts maintained their "Buy" rating on Eli Lilly and raised the price target from $1,419 to $1,430.

2. On October 6, Eli Lilly expanded its collaboration with Gate Bioscience, obtaining exclusive global rights to related products. If development milestones are achieved, the potential payment could exceed $870 million, further expanding its innovative drug pipeline.

(Disclaimer: This content is compiled and summarized by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)